Login to Your Account



Prexton raises $31M for mGluR4 agonist drug targeting Parkinson’s disease

By Cormac Sheridan
Staff Writer

Tuesday, February 7, 2017

DUBLIN – Prexton Therapeutics SA raised €29 million in a series B round to conduct two phase II trials in Parkinson’s disease of its metabotropic glutamate receptor 4 (mGluR4) agonist, foliglurax (PXT002331).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription